Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Orion, Webcast, Q3'25

By Inderes10/28/2025, 11:30 AM
Orion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Tuukka Hirvonen
00:01 - 01:45

Oikein hyvää iltapäivää ja tervetuloa mukaan seuraamaan Orionin tulosjulkistustilaisuutta katsauskaudelta tammi-syyskuu 2025. Minun nimeni on Tuukka Hirvonen ja vastaan Orionilla sijoittajasuhteista. Hetken kuluttua toimitusjohtajamme Liisa Hurme esittelee katsauskauden tuloksen, jonka jälkeen teillä on mahdollisuus esittää kysymyksiä niin hänelle kuin talousjohtaja René Lindellillekin. Tämän tilaisuuden virallinen kieli on englanti, mutta kysymyksiä voi esittää myös suomeksi. Lisäksi myöhemmin tämän iltapäivän aikana toimitusjohtaja Liisa Hurmeen suomenkielinen haastattelu julkaistaan Orionin verkkosivuilla. Good afternoon and welcome to Orion's earnings conference call and webcast for the financial period of January to September. Vuonna 2025. My name is Tuukka Hirvonen, and I'm the head of investor relations here at Orion. After which we will have a Q&A session where you can post questions both to Liisa and also to our CFO. René Lindell, we will first take questions from the conference call lines and after that, we will turn to the webcast questions. And just before I let Liisa take the stage, I'd like to draw your attention to the disclaimer regarding forward-looking statements. Liisa.

Liisa Hurme
01:45 - 19:13

Thank you, Tuukka, and welcome to Orion's Q3 webcast on my behalf as well. Nubeqa saavutti myös kaikkien aikojen korkeimmat rojaltit ja tuotelähetykset Bayerille kolmannella neljänneksellä. Availability of products in our mature markets and very successful new launches. Valitettavasti ODM-105 tasipimidine -vaiheen 2 tutkimus unettomuuteen ei saavuttanut tavoitteitaan. Efficacy target, and we decided to discontinue the development of that program. And Q3 financials are here, and before I go deeper into the financials. On hyvä muistaa, että vertailujakso Q3 vuonna 2024 oli poikkeuksellinen neljännes. We received one hundred and thirty million worth of milestones last year. Q3. There was a seventy million sales milestone from Bayer related to Nubeqa® and a sixty million milestone. Liittyen MSD:n ja Opevesostat-sopimukseen on vaikeaa verrata näitä keskenään, ja nyt kun jatkan. I will talk about the base business, which is the business excluding the milestones. The base business growth was twenty-four percent from quarter three last year to this year's quarter three, totaling 423 million in operating profit. Growth was even stronger at sixty-eight percent, up to one hundred and one million euros. Q3. The milestones were booked but had not yet been paid out, so they were not yet cash in our bank. And when we look closer at the net sales bridge. We can see the net effect of the difference between the quarters here regarding the milestones in the innovative medicines column, which is fifty-nine million. Milestones, we can also see here that all other divisions developed positively, with the strongest growth in generics and consumer health. Tässä on operatiivisen voiton silta. We can see the full impact of the effects from previous years. Milestones reached one hundred and thirty million euros, with positive changes in sales volume, price adjustments, and cost of goods and product mix, overall. Twenty million and then the royalties of fifty million. We can also see that our fixed costs increased as well, but this is all planned. It is mainly our R&D and sales and marketing costs here. Now let's take a view for the first nine months from January to September again, a very nice twenty-two percent growth during the first nine months and seven point eight percent growth. Even though we compare to the previous year's quarter three including the milestones, the first three months end up with one point two billion of net sales, recording an operating profit of fifty-seven million, a fifty-seven percent growth, and slight decrease. If we compare to the numbers including milestones in the previous year, there was a very positive development in cash flow during the first nine months. Now to innovative medicines. This is a bit of a different picture than you are used to seeing. There is the shaded area which tries to show you the comparison between the quarters, excluding everything else but the milestones from the previous year, and seventy-one percent growth is very healthy for innovative medicines. Here you can see the all-time high royalties and product deliveries, totaling one hundred and sixty-six million, and I always remind looking at this picture. The very. How do I say the year is very back-end loaded for Nubeqa. As you can see here when you look at the figures from the first quarter to the last quarter, but here as well, I would like to remind you that in comparison to the previous year. We already reached the higher royalty rate in the previous quarter with Nubeqa, so we are not going to see a similar shift and change in the royalty rate as we saw last year between Q3 and Q4. Branded products growth during Q3 was somewhat low. Kasvu oli kolme prosenttia, ja tämä kasvun hitaus johtuu pääasiassa toimitusten ajoituksesta Stalevo-kumppaneillemme, ja tämä korjataan loppuvuoden aikana. The product was the clear driver for the growth, and then in the CNS portfolio, Stalevo Japan contributed to growth in branded products. And as I say generics and Consumer Health's quarter. Three was very, very strong. Five point four percent growth is extremely good for any generic business, but especially here when we remember that Simdax and Dexdor are included in this business and they are constantly sliding down facing the generic competition. The service level is crucial in the generic business. You need to have the products available at the time of the tender where they should be, and you need to be able to deliver to all the different countries in their specific timing, often under specific pricing processes. Animal Health continued. The good growth trend continues here, although we see a bit of a similar slowdown as with branded products, and that partly has to do with deliveries as well. On the top ten product list, Nubeqa has been flagged as a key product with a growth of around three percent. Helppokäyttöisen inhalaattorituoteportfolion kasvu oli lähellä edellisvuotta, ja Entakaponi-tuotteen kasvu oli lähellä viittä prosenttia, pääasiassa Japanin myynnin ansiosta. Even though we are presenting growth close to their current state, our ABB products demonstrate growth, and currently, our business divisions are very healthy. The balance between business divisions is very healthy; approximately thirty percent for innovative medicines and generics, and close to twenty percent for branded products. Now Orion's clinical development pipeline has clearly become oncology-focused as we decided to discontinue the ODM-105 project for the treatment of insomnia. We have also removed darolutamide from this list as it's approved both in the US and EU, so we now have the duscial hicap study on this list and then the two Omaha studies with Opevesostat that Emmes is responsible for, it is good to mention. In these two Opevesostat studies, the design and primary endpoints have changed since we last presented this, so that for the Omaha 3, which is for the later line patients. The primary endpoint is now overall survival, so the progression-free survival has been demoted, and overall survival is the primary endpoint. Also, there are changes for the frontline patients study. To this end, the progression-free survival is now a primary endpoint for this study. These are changes that we made with our partner. MSD has done this, and it looks very logical in all possible ways. Then we have the ACCES levosimendan study for pulmonary hypertension progressing in Phase 3, with plans to start another Phase 3 study by the end of this year. Another global study for this indication and then we have another study for Opevesostat for metastatic castration-resistant prostate cancer, as well as three phase two studies ongoing for several or three different women's hormonal cancers: breast, endometrial, and ovarian cancer. We have four solid tumors proceeding well in phase one, and we are preparing to start the phase two program in the first half of next year. Sitten viisi sanaa kestävyydestä. This time, regarding decarbonization targets, we have set an ambitious target to reduce absolute scope 1 and 2 greenhouse gas emissions by seventy percent by the year 2030. 2030 and also have 78 percent of our suppliers. Meaning scope three emissions. Tavoitteidemme piiriin kuuluu se. I think for Scope 1 and 2, we have very concrete actions ongoing. Steam production is one of the most energy-consuming phases in the chemical industry, especially in the API industry, and we are changing the energy source for steam production in all of our manufacturing facilities in Turku. We are electrifying the steam production in Oulu. We are changing to biofuels from fossil fuels, and we will also start an electrifying project in Espoo. Joten erittäin konkreettisia esimerkkejä täällä, ja olemme jo tehneet paljon konkreettisia toimia ja projekteja ennen tätä, esimerkiksi Honkon tehtaalla ja toimittajahallinnassa. We are targeting our highest emitting suppliers. We are not yet. Aligned with SBTi, we try to offer support and practices and technical expertise with our suppliers. Ja olemme tänään tarkentaneet näkymiämme. Our operating outlook for operating profit. We have narrowed from four hundred ten to four hundred ninety million euros, so nothing drastic; we've been able to narrow it as the year has ten months already past. There are two months left, and we have a much clearer view on how the year will pan out, especially regarding net sales. Our outlook is from 1,640 million to 1,720 million euros. And here you can see the upcoming events for next year, and I thank you on my behalf and welcome Rene here with me to answer your questions.

Tuukka Hirvonen
19:14 - 19:33

Kiitos mainiosta esityksestä. As we said in the beginning, we will first take questions from the conference call lines, and then we will turn to the questions you can type in through the chat function in the webcast.

Operator
19:35 - 19:58

If you wish to ask a question, please dial pound key five. On your telephone keypad to enter the Q. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Samsa Ms from Danske Bank Markets. Please go ahead.

Unknown 1
20:00 - 20:21

Hi. I have four questions and will take them one by one, starting firstly with the guidance. Can you elaborate on what is driving the small revisions to the lower and upper ends of the guidance range? Is it about third quarter actuals or have you also updated your forecasts for the first quarter?

Liisa Hurme
20:23 - 21:13

Well, of course, the first thing is to mention that we now know how the first seven months have passed and there are only two months left, but there are, of course, uncertainties for the latter part of the year. Nubeqa is a big moving factor in this, and also regarding costs, and their tariffs are not that significant here. We do think that they won't have any effect this year 2025, but there are still uncertainties for the rest of the year, so we still have this range. Refine. Narrow. The range.

Unknown 1
21:17 - 21:36

Okay, then moving on to growth momentum in branded products and animal health, third quarter growth rates are clearly weaker than what we saw in the second quarter. How would you explain that and what is your expectation regarding it? Q4.

Liisa Hurme
21:38 - 22:43

Vuosia. You're quite correct that the branded products and animal health sectors show slower growth compared to earlier this year. Hitaampi kasvu tänä vuonna johtuu pääasiassa viivästyksistä toimituksissamme kumppaneille. Meillä on sekä eläinterveys että Animal Health, jotka itse asiassa työskentelevät tiiviisti yhdessä. If there are big deliveries happening, the same goes for branded products, as we continue to deliver to our Stalevo partners across the world and it is the same situation. I think we experienced this earlier years as well that sometimes it just happens that we are not able to ship during the quarter as we had planned, but this should be sorted out. We should be able to sort this out by the end of the year during the Q4.

Unknown 1
22:47 - 23:02

Asiakirjojen siirrytessä kolmanteen kysymykseen vanhasta mtoathumaatioista, siinä työssä on muutettu Omaha-tutkimusten ensisijaisia päätepisteitä, milloin tämä muutos tehtiin.

Liisa Hurme
23:05 - 23:10

This change became public. I think a month ago or perhaps three weeks ago it might have been.

Tuukka Hirvonen
23:10 - 23:27

Noin viikko sitten, lokakuun alussa, he muuttivat protokollia. It was visible in the clinical trials data. Se ei ole mitään materiaalista, koska emme julkaisseet sitä siinä vaiheessa, mutta tietenkin, nyt on jotain erittäin mielenkiintoista kaikille teille, joten haluamme korostaa sen siellä.

Unknown 1
23:30 - 24:12

Hienoa, ja sitten lopuksi Orionin kehitysohjelmasta ensi vuoden osalta. Can you provide a bit more detail on when you expect a Phase 1 readout for the old? Expectantly, when do you anticipate initiating the first Phase 2 study for that molecule, and secondly at CMD, you mentioned three biological preclinical programs. Moving into phase one during next year, could you check if these projects are still active as you are currently guiding for at least one new program during next year.

Liisa Hurme
24:12 - 24:55

Everything starts with ODM-105 as a compound. Phase one is almost completed. Olemme tarkastelemassa tuloksia ja perustamme vaiheen 2 suunnittelun näihin tuloksiin, tietysti. We will report the results in some form for the upcoming scientific meeting. It's currently under planning. We have filed the IND for that and hope to be starting by hopefully mid-2026. What is the then there was one more.

Tuukka Hirvonen
24:56 - 24:57

About the biologics.

Liisa Hurme
24:57 - 25:12

Bayer USA indeed. Yes, we mentioned that we have three biologics close to advancing to the clinical pipeline, and we think that we will be able to proceed with at least one of them to phase one next year.

Unknown 1
25:15 - 25:17

Okay, thanks. I don't have any further questions.

Operator
25:21 - 25:36

As a reminder, if you wish to ask a question, please dial the pound key five on your telephone keypad. Alkaa. The next question comes from Sean. Hamar Jeffriesiltä. Ole hyvä ja jatka.

Unknown 2
25:38 - 26:01

Thank you for taking my questions. It is not significant, but perhaps any guidance on the provision side would be helpful. They are helpful.

René Lindell
26:04 - 26:50

Maybe you can take that one, so of course regarding the audio. ODM-105 received the results, and in such a way, you could say the project was completed. So from this perspective, there is not a big impact in terms of how we expected this year's outcomes. Our R&D expenses will align with what was in our plans, and as it was completed, of course for next year, you can expect a change in how the budget is allocated. One out of five, of course, is not moving forward. There are some tail costs for next year that will be taken into this year, but overall it has been quite a new experience for this year compared to what we save and whatever provisions. We account for costs that would have occurred next year.

Unknown 2
26:52 - 27:14

Thank you, and secondly, I mean you. I would specify your guidance on the initiatives increasing visibility on the format of the businesses. IAS visibility on the milestone should also be better.

Liisa Hurme
27:16 - 27:48

Well, as we have started, we think that we will receive the milestone next year (2026), but it is possible that we receive that milestone already in 2025. It’s next year.

Unknown 2
27:50 - 28:07

Understood, thank you, and finally, given the delay you mentioned in the deliveries in branded production. Animal health is forecasted to expect a lift in Q4 assuming these deliveries are made as well as the normal business expected in full QS. It's more of a pull-through dynamic.

Liisa Hurme
28:08 - 28:11

I didn't quite get the question, could you repeat it?

Tuukka Hirvonen
28:12 - 28:20

It's about the timing of shipments in branded products and animal health since we now show some headwinds; will there be better conditions in Q4?

Liisa Hurme
28:20 - 28:29

Now that I think about it, it's just according to plan that we get the milestone, so it is not boosting the Q4.

Unknown 2
28:31 - 28:33

Anders, third. Thank you, don't take my questions.

Operator
28:38 - 28:45

The next question comes from Mathy Carroler from OP Corporate Bank. Please go ahead.

Unknown 3
28:48 - 29:17

Hei tämä. Motto Kolekysto Nubeqa® related questions. First, regarding the US situation and the pricing, I know you are not willing to say much about it, but could you maybe say a little bit about the political atmosphere? Ovatko sinä ja kumppanisi? Is there pressure to lower the price, or what is your outlook right now? If you look on the other side of the Atlantic.

Liisa Hurme
29:19 - 29:56

Well, I think that's a good question regarding the US business environment. However, I think the question of whether our partner is under pressure or needs to change the price is relevant. I think it's fair to say that this needs to be asked from Bayer. It's not my place to comment on that matter, but in general, there are a lot of things happening in the U.S. regarding the pricing, the most favoured nation initiative, and also, of course, the tariffs. So we follow the situation carefully.

Unknown 3
30:00 - 30:31

All right, thank you. When did you receive the latest permit in the US during the summer and also in Europe? Concerning the latest medication, have you seen a significant volume change or any change in the sales during the new three months? If we speak about the range of adoption rates, they are early and there is another aspect of sales indication. This is visible after you got the final Therese beer mix.

Liisa Hurme
30:33 - 31:09

Well, we don't. Of course, we see that the volume is increasing, and that's a very positive thing, but we don't have a kind of a step change. If you are referring to that with the new indication, it's more of a linear growth, so it is. It's very positive. I'm sure that it has a positive effect as it can be used also without docetaxel, but we don't see exactly a kind of step change in big growth there yet.

Unknown 3
31:12 - 31:13

Thank you for taking my questions.

Operator
31:17 - 31:33

Muistutuksena, jos haluatte esittää kysymyksen, valitkaa puhelimen näppäimistöltä ruutunäppäin ja numero viisi. The next question comes from an audience member from ACB. Please go ahead.

Unknown 1
31:36 - 31:37

Yes, hi Leena.

Unknown 3
31:37 - 32:05

Thank you for the presentation. One question from me and it's just to double-check something mentioned during the presentation about Nubeqa royalties in Q4 compared to Q3.

Liisa Hurme
32:05 - 32:18

Very good that you asked. Yritin selittää, että viime vuonna. The royalty rate changes between Q3 and Q4, so.

Tuukka Hirvonen
32:18 - 32:19

During Q4.

Liisa Hurme
32:19 - 32:58

Q for you. It was not exactly between, but during Q4, so it had an impact such that the Q4 was clearly higher in Nubeqa sales royalties. Tänä vuonna saavutimme jo sen rojaltikoron kolmen kuukauden aikana, joten vaikka myös rojaltit tulevat olemaan kaikki, The sales will be growing, so there will be a kind of double effect of sales growth and royalty percentages increasing during quarter two, so that's the difference. I do not know if I explained it well or if my colleague wants to explain it even better.

Unknown 3
33:01 - 33:18

Good, and so if your royalty rate closed the gap during quarter three, was it at the end of the quarter, or was the average rate already capped and will be similar in quarter four, or is it like the run rate at the end of quarter three.

Tuukka Hirvonen
33:21 - 33:55

We reached the gap during Q3, not going into specifics about which point in time, but the message was that one could not expect a similar step-up as seen last year between Q3 and Q4.

Unknown 3
33:58 - 33:59

Okei, tarkennanko?

Operator
34:03 - 34:05

There are no more questions at this time.

Tuukka Hirvonen
34:07 - 34:49

Aivan? We cutting the latest medication, have you seen a significant volume change or gain of any change about the sales during the new three. Operator, then we turn to the chat questions. We have a couple here; you still have time to type in more. If you have anything on your mind. Let's start with one; this is actually already covered, but just to let you know that our audience is asking if it is still realistic to think that the one hundred million Nubeqa® milestone would come already this year. A milestone would come already this year and actually you have already addressed that question, so that is covered. Comments.

Liisa Hurme
34:51 - 35:24

I think there are no specific comments on that. I think we are more or less following all the sales development, and as I said, it's steadily growing, so we haven't really seen any step up due to approval. That's what we've been trying to tell all along while we've been waiting for the Nubeqa approval.

Tuukka Hirvonen
35:27 - 35:41

All right. Thank you, Lease. We have now further questions in the chat, but I could a message will actually now. Iiris has a follow-up here, so why? Administration costs were lower year on year, and what would you expect for the future?

René Lindell
35:43 - 36:14

Typically, there are quite many line items, and some of these can just shift from quarter to quarter. They are quite minor changes in terms of the overall admin expenses. This is nothing, nothing big changing the normal inflation which is now across the board, but I would not expect any drastic differences, right.

Tuukka Hirvonen
36:14 - 36:35

Thanks Reneth, then we have a follow-up from Sami Sarkamies from Danske. Seuraten muutoksia päätepisteissä audiemzoatelle, Opevesostat Omaha -kokeille. Do you still foresee an interim readout? Twenty six before you answer, of course. We need to point out that we have never estimated or foreseen that there will be a readout.

Liisa Hurme
36:36 - 36:44

Interim read and then, you know, but I think it's public when the readout for the full.

Tuukka Hirvonen
36:44 - 36:48

Saat täyden lukuajon. Yes, but the interim readout now.

Liisa Hurme
36:48 - 36:55

Emme aio kommentoida sitä, koska emme ole koskaan kommentoineet sitä, mutta molempien tutkimusten tulokset pitäisi saada vuoden kahdenkymmenenyhdeksän aikana.

Tuukka Hirvonen
36:57 - 37:23

Yes, that's correct. He says that your R&D costs have been increasing clearly.

Liisa Hurme
37:24 - 37:46

We are clearly focusing on the development programs that are in our hands. I would say that would be early to 2030s.

Tuukka Hirvonen
37:50 - 38:09

All right. Thank you, Leisa. Now we have exhausted all the questions from the chat and also the EC, and there are messages that there are no follow-ups in the conference call lines, so it's time for us to wrap up. Thank you for joining us today and have a great rest of the day and week.

Liisa Hurme
38:11 - 38:11

Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…